22.07.2013
- Vivus has agreed to give dissident shareholder First Manhattan a board majority, ending an acrimonious proxy fight and bringing in a new CEO to the drugmaker accused of bungling...
18.07.2013
- Obesity drug maker Vivus, embroiled in a bitter proxy war with its top shareholder First Manhattan, said on Wednesday that FMC had rejected an offer to give the sides equal...
11.07.2013
- QVT Financial, the third-largest shareholder in obesity drugmaker Vivus, intends to vote for the full slate of nine directors proposed by dissident investor First Manhattan, a...
03.07.2013
- Vivus' largest shareholder on Tuesday took the unusual step of naming the man it would install as the drugmaker's chief executive should it prevail in its battle to gain control of...
26.06.2013
- First Manhattan Company (FMC) stepped up the pressure in its proxy fight with obesity drug maker Vivus, saying it was in advanced discussions with potential chief executive...
07.01.2013
- Vivus said prescriptions for obesity drug Qsymia, its main product, rose nearly 68% in the month ended Dec. 21 compared with the preceding four weeks, well above industry forecasts...
28.06.2012
- U.S. health regulators approved the first new weight-loss drug in 13 years, allowing Arena Pharmaceuticals to bring its Belviq pill to market as public health advocates push for...
